輝瑞季報數據現轉折跡象

• Pfizer reports first YoY revenue growth since Q4 2022, reaching 192M+ patients in H1 2024
• Company raises full-year revenue and earnings guidance for 2024, signaling optimism
• Focus on oncology leadership, pipeline innovation, and shareholder value; Seagen integration progressing
• Cost-realignment and manufacturing optimization expected to save $1.5B+ by 2027
• Confident in navigating IRA impact; core business strong with key products showing notable performance

Pfizer reported a YoY revenue growth not seen since the final quarter of 2022

所有跟帖： 

• 買了1-2 年了， 在水下 15%. 有股息。 -大百百- ♂ (0 bytes) () 04/29/2025 postreply 10:08:21

• 是否了解 BIG PHARM? 那些前景比較好？ -大百百- ♂ (0 bytes) () 04/29/2025 postreply 10:13:12